18,685 DaVita Inc. $DVA Shares Acquired by Counterpoint Mutual Funds LLC

Key Points

• Counterpoint Mutual Funds increased its DaVita stake by 56.3% in the third quarter, acquiring 18,685 shares and bringing its total holdings to 51,875 shares valued at approximately $9.1 million.
• DaVita reported quarterly revenue of $3.55 billion and earnings of $4.02 per share, exceeding analyst estimates, while revenue increased 5.2% year over year. The company issued fiscal 2026 EPS guidance of $14.10–$15.20.
• Analyst sentiment remains positive but mixed, with four Buy ratings and three Holds; DaVita carries a “Moderate Buy” consensus rating and an average price target of $233.43, compared with its $187.16 share price.

Counterpoint Mutual Funds LLC lifted its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 56.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,875 shares of the company's stock after acquiring an additional 18,685 shares during the period. Counterpoint Mutual Funds LLC owned approximately 0.08% of DaVita worth $9,074,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Pension & Wealth Management Advisors Inc. purchased a new position in DaVita during the third quarter worth about $164,000. V Square Quantitative Management LLC raised its holdings in shares of DaVita by 34.5% in the 3rd quarter. V Square Quantitative Management LLC now owns 1,859 shares of the company's stock worth $325,000 after purchasing an additional 477 shares during the period. State of Alaska Department of Revenue grew its holdings in DaVita by 1.9% during the third quarter. State of Alaska Department of Revenue now owns 3,206 shares of the company's stock valued at $560,000 after purchasing an additional 60 shares during the period. Curated Wealth Partners LLC purchased a new stake in DaVita in the 3rd quarter worth about $3,478,000. Finally, Krilogy Financial LLC purchased a new position in shares of DaVita in the third quarter worth about $312,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Stock Performance

Shares of NYSE DVA opened at $187.16 on Friday. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $247.49. The company has a market cap of $11.94 billion, a PE ratio of 15.32, a P/E/G ratio of 0.49 and a beta of 0.80. The firm's 50 day moving average price is $180.47 and its 200-day moving average price is $190.56.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping analysts' consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%. The business had revenue of $3.55 billion during the quarter, compared to analyst estimates of $3.50 billion. During the same quarter last year, the company earned $2.95 EPS. The company's quarterly revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, analysts forecast that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on DVA. Oppenheimer set a $220.00 price objective on DaVita in a research note on Friday, August 7th. UBS Group increased their price target on shares of DaVita from $235.00 to $270.00 and gave the company a "buy" rating in a research report on Friday, July 10th. Truist Financial decreased their price target on DaVita from $250.00 to $215.00 and set a "hold" rating on the stock in a research note on Friday, August 7th. Zacks Research cut shares of DaVita from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 6th. Finally, TD Cowen upgraded DaVita from a "hold" rating to a "buy" rating and lifted their price objective for the stock from $201.00 to $220.00 in a research report on Friday, August 7th. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, DaVita has an average rating of "Moderate Buy" and a consensus price target of $233.43.

DaVita Profile

DaVita Inc is a healthcare company focused on kidney care and renal disease management. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with end-stage kidney disease, including hemodialysis and peritoneal dialysis, as well as home dialysis support.

The company also operates hospital-based dialysis programs and offers clinical, administrative and care-coordination services intended to support patients across the kidney-care journey.

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.